2611005616
  • Open Access
  • Article

Neuropharmacological Evaluation of the Mangrove Plant Xylocarpus granatum J. Koenig Fruit Extract: Anxiolytic-Like and Sedative Profile in Murine Models

  • H. M. Shadid Hossain Snigdha 1,2,   
  • Rokibul Islam Chowdhury 2,   
  • Anik Kumar Saha 2,   
  • Balaram Das 2,   
  • Tasfiya Rufaidah Ahnaf 1,   
  • Md Arshadul Hoque 2,   
  • Shoyaeb Ahammed 2,   
  • Md. Sabbir Hosain 2,   
  • Md Shourov Hossen 2,   
  • Razina Rouf 2,   
  • Jamil A. Shilpi 1,   
  • Muhammad Torequl Islam 2,3 and 
  • Shaikh Jamal Uddin 1,*

Received: 28 September 2026 | Revised: 06 November 2026 | Accepted: 09 November 2026 | Published: 19 November 2026

Abstract

The fruit extract of Xylocarpus granatum J. Koenig (Meliaceae) is rich in bioactive phytoconstituents with documented pharmacological activities, but its precise role in modulating neurological disorders remains insufficiently understood. The present study was designed to evaluate the anxiolytic-like and sedative potentials of X. granatum fruit extract (XGFE) using established in vivo experimental models. To assess behavioral, locomotor, and exploratory parameters associated with anxiolytic-like activity, Swiss albino mice were divided into experimental groups and treated with diazepam (1 mg/kg), flumazenil (0.1 mg/kg), and XGFE (250 and 500 mg/kg) across four distinct behavioral paradigms (the open-field, hole-cross, swing, and light-dark tests). Sedative activity was subsequently assessed using the thiopental sodium-induced sleeping test to measure sleep latency and duration. Treatment with XGFE (250 and 500 mg/kg) elicited significant (p < 0.05) decreases in locomotor and exploratory measures, thereby indicating an anxiolytic-like calming effect. In addition, XGFE (500 mg/kg) reduced sleep latency to 19.2 min (NC: 30.4 min) and prolonged sleep duration to 147.2 min (NC: 47.2 min), indicating a potential sedative effect in mice. Moreover, co-administration of XGFE alongside diazepam (DZP) at 3 mg/kg prolonged the duration of CNS-depressant activity (177 min). Thus, the present findings indicate that XGFE exhibits anxiolytic-like and sedative effects, suggesting its possible utility as a naturally derived therapeutic candidate for neurological management.

References 

  • 1.

    Kishanrao, S. Epidemiology & Management of Insomnia in Smaller Settings. Int. J. Clin. Epidemiol. 2023, 2, 1–4. https://doi.org/10.31579/2835-9232/019.

  • 2.

    Garbarino, S.; Lanteri, P.; Durando, P.; et al. Co-Morbidity, Mortality, Quality of Life and the Healthcare/Welfare/Social Costs of Disordered Sleep: A Rapid Review. Int. J. Environ. Res. Public Health 2016, 13, 831. https://doi.org/10.3390/ijerph13080831.

  • 3.

    Zhang, Y.; Ren, R.; Lei, F.; et al. Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: A systematic review and meta-analysis. Sleep Med. Rev. 2019, 45, 1–17. https://doi.org/10.1016/j.smrv.2019.01.004.

  • 4.

    Lakhera, K.P. Anxiety-A theoretical analysis. Quest J. UGC-HRDC Nainital 2018, 12, 241–246. https://doi.org/10.5958/2249-0035.2018.00035.9.

  • 5.

    Siddhant, M.; Sharad, K.; Ajay, D.; et al. Impact of Anxiety Disorders on Daily Functioning of an Individual—In Terms of Family, Social life, School and Work. J. Reatt. Ther. Dev. Divers. 2023, 6, 56–63. https://doi.org/10.67145/jrtdd.v6i4s.418.

  • 6.

    Javaid, S.F.; Hashim, I.J.; Hashim, M.J.; et al. Epidemiology of anxiety disorders: Global burden and sociodemographic associations. Middle East Curr. Psychiatry 2023, 30, 44. https://doi.org/10.1186/s43045-023-00315-3.

  • 7.

    Nguyen, V.V.; Zainal, N.H.; Newman, M.G. Why Sleep is Key: Poor Sleep Quality is a Mechanism for the Bidirectional Relationship between Major Depressive Disorder and Generalized Anxiety Disorder across 18 Years. J. Anxiety Disord. 2022, 90, 102601. https://doi.org/10.1016/j.janxdis.2022.102601.

  • 8.

    Bisaga, A.; Mariani, J.J. Benzodiazepines and other sedatives and hypnotics. In The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 5th ed.; Galanter, M., Kleber, H.D., Brady, K.T., eds.; American Psychiatric Publishing, Inc.: Arlington, VA, USA, 2015; pp. 239–262. https://doi.org/10.1176/appi.books.9781615370030.mg17.

  • 9.

    Davis, E.M.; Ramani, C.; Quigg, M. Neurologic Manifestations of Systemic Disease: Sleep Disorders. Curr. Treat. Options Neurol. 2020, 22, 30. https://doi.org/10.1007/s11940-020-00639-z.

  • 10.

    Hovens, J.G.F.M.; Giltay, E.J.; Wiersma, J.E.; et al. Impact of childhood life events and trauma on the course of depressive and anxiety disorders. Acta Psychiatr. Scand. 2012, 126, 198–207. https://doi.org/10.1111/j.1600-0447.2011.01828.x.

  • 11.

    Meuret, A.E.; Tunnell, N.; Roque, A. Anxiety Disorders and Medical Comorbidity: Treatment Implications. In Anxiety Disorders: Rethinking and Understanding Recent Discoveries; Kim, Y.-K., ed.; Springer Singapore: Singapore, 2020; pp. 237–261. https://doi.org/10.1007/978-981-32-9705-0_15.

  • 12.

    Alamgir, M.; Uddin, S.J. Recent advances on the ethnomedicinal plants as immunomodulatory agents. In Ethnomedicine: A Source of Complementary Therapeutics; Chattopadhyay, D., ed.; Research Signpost: Kerala, India, 2010; pp. 227–244.

  • 13.

    Ashrafuzzaman, M.D.; Raju, G.S.; Abeer, M.I.U.; et al. Antidiarrheal Activity of Three Medicinal Plants in Swiss Albino Mice. Int. J. Biomed. 2016, 6, 233–236. https://doi.org/10.21103/article6(3)_oa16.

  • 14.

    Chowdhury, R.; Bhuia, M.S.; Al Hasan, M.S.; et al. Anticancer potential of phytochemicals derived from mangrove plants: Comprehensive mechanistic insights. Food Sci. Nutr. 2024, 12, 6174–6205. https://doi.org/10.1002/fsn3.4318.

  • 15.

    Nabeelah Bibi, S.; Fawzi, M.M.; Gokhan, Z.; et al. Ethnopharmacology, Phytochemistry, and Global Distribution of Mangroves—A Comprehensive Review. Mar. Drugs 2019, 17, 231. https://doi.org/10.3390/md17040231.

  • 16.

    Snigdha, H.M.S.H.; Islam, M.M.; Rouf, R.; et al. Hepatoprotective Effects of Mangrove Plant Species of the Sundarbans and Their Bioactive Metabolites: A Comprehensive Review with Mechanistic Insights. J. Food Biochem. 2026, 2026, 4030443. https://doi.org/10.1155/jfbc/4030443.

  • 17.

    Chavan, S.S.; Shamkuwar, P.B.; Damale, M.G. Phytochemical and pharmacological potential of mangroves: A comprehensive review on traditional uses and medicinal prospects. Pharmacol. Res. Nat. Prod. 2026, 10, 100485. https://doi.org/10.1016/j.prenap.2025.100485.

  • 18.

    Lakshmi, V.; Singh, N.; Shrivastva, S.; et al. Gedunin and Photogedunin of Xylocarpus granatum show significant anti-secretory effects and protect the gastric mucosa of peptic ulcer in rats. Phytomedicine 2010, 17, 569–574. https://doi.org/10.1016/j.phymed.2009.10.016.

  • 19.

    Das, S.K.; Prusty, A.; Samantaray, D.; et al. Effect of Xylocarpus granatum Bark Extract on Amelioration of Hyperglycaemia and Oxidative Stress Associated Complications in STZ-Induced Diabetic Mice. Evid. Based Complement. Altern. Med. 2019, 2019, 8493190. https://doi.org/10.1155/2019/8493190.

  • 20.

    Bhuia, M.S.; Rokonuzzman, M.; Hossain, M.I.; et al. Anxiolytic-like Effects by trans-Ferulic Acid Possibly Occur through GABAergic Interaction Pathways. Pharmaceuticals 2023, 16, 1271. https://doi.org/10.3390/ph16091271.

  • 21.

    Shahed-Al-Mahmud, M.; Lina, S.M.M. Evaluation of sedative and anxiolytic activities of methanol extract of leaves of Persicaria hydropiper in mice. Clin. Phytosci. 2017, 3, 20. https://doi.org/10.1186/s40816-017-0056-5.

  • 22.

    Mia, M.N.; Smrity, S.Z.; Bappi, M.H.; et al. Anxiolytic-like effect of succinic acid: A possible GABAergic intervention. Food Biosci. 2023, 55, 103044. https://doi.org/10.1016/j.fbio.2023.103044.

  • 23.

    Hassan, S.M.H.; El-Nashar, H.A.S.; Rahman, M.A.; et al. Sclareol antagonizes the sedative effect of diazepam in thiopental sodium-induced sleeping animals: In Vivo and in silico studies. Biomed. Pharmacother. 2024, 176, 116939. https://doi.org/10.1016/j.biopha.2024.116939.

  • 24.

    Mukty, S.A.; Hasan, R.; Bhuia, M.S.; et al. Assessment of sedative activity of fraxin: In Vivo approach along with receptor binding affinity and molecular interaction with GABAergic system. Drug Dev. Res. 2024, 85, e22250. https://doi.org/10.1002/ddr.22250.

  • 25.

    Yu, X.; Li, G.; Liu, J.; et al. Anxiolytic Effects of Natural Products: Pathological Mechanisms, Molecular Targets, Therapeutic Prospects. Neuropsychiatr. Dis. Treat. 2025, 21, 2623–2653. https://doi.org/10.2147/ndt.s571692.

  • 26.

    O’Leary, K.B.; Khan, J.S. Pharmacotherapy for Anxiety Disorders. Psychiatr. Clin. North Am. 2024, 47, 689–709. https://doi.org/10.1016/j.psc.2024.04.012.

  • 27.

    Kandola, A.; Vancampfort, D.; Herring, M.; et al. Moving to Beat Anxiety: Epidemiology and Therapeutic Issues with Physical Activity for Anxiety. Curr. Psychiatry Rep. 2018, 20, 63. https://doi.org/10.1007/s11920-018-0923-x.

  • 28.

    Islam, F.; Akter, A.; Mimi, A.A.; et al. Neuropharmacological Effects of Chassalia curviflora (Rubiaceae) Leaves in Swiss Albino Mice Model. Arch. Razi Inst. 2022, 77, 881–890. https://doi.org/10.22092/ari.2021.356880.1937.

  • 29.

    Benjafield, A.V.; Sert Kuniyoshi, F.H.; Malhotra, A.; et al. Estimation of the global prevalence and burden of insomnia: A systematic literature review-based analysis. Sleep Med. Rev. 2025, 82, 102121. https://doi.org/10.1016/j.smrv.2025.102121.

  • 30.

    Deng, Q.; Chen, H. Trends in Benzodiazepine and Z-Drug Prescriptions in Eastern China (2015–2021). Alpha Psychiatry 2025, 26, 38792. https://doi.org/10.31083/ap38792.

  • 31.

    Abdel-Aziz, S.M.; Aeron, A.; Kahil, T.A. Health Benefits and Possible Risks of Herbal Medicine. In Microbes in Food and Health; Garg, N., Abdel-Aziz, S.M., Aeron, A., eds.; Springer International Publishing: Cham, Switzerland, 2016; pp. 97–116. https://doi.org/10.1007/978-3-319-25277-3_6.

  • 32.

    Dey, D.; Quispe, C.; Hossain, R.; et al. Ethnomedicinal Use, Phytochemistry, and Pharmacology of Xylocarpus granatum J. Koenig. Evid. Based Complement. Altern. Med. 2021, 2021, 8922196. https://doi.org/10.1155/2021/8922196.

  • 33.

    Cheng, F.; Zhou, Y.; Zou, K.; et al. Studies on the chemical constituents of the fruit of Xylocarpus granatum (In Chinese). J. Chin. Med. Mater. 2009, 32, 1220–1223.

  • 34.

    Shi, X.; Wu, Y.; Lv, T.; et al. A chemometric-assisted LC–MS/MS method for the simultaneous determination of 17 limonoids from different parts of Xylocarpus granatum fruit. Anal. Bioanal. Chem. 2017, 409, 4669–4679. https://doi.org/10.1007/s00216-017-0413-8.

  • 35.

    Tundis, R.; Loizzo, M.R.; Menichini, F. An Overview on Chemical Aspects and Potential Health Benefits of Limonoids and Their Derivatives. Crit. Rev. Food Sci. Nutr. 2014, 54, 225–250. https://doi.org/10.1080/10408398.2011.581400.

  • 36.

    Takahashi, M.; Yoneda, Y.; Kuriyama, K. Enhancement of γ-aminobutyric acid (GABA) receptor binding by lipophilic antioxidants. Brain Res. 1984, 296, 164–167. https://doi.org/10.1016/0006-8993(84)90525-0.

  • 37.

    Alam, M.A.; Awal, M.A.; Subhan, N.; et al. Sedative, Neuropharmacological and Antinociceptive Effect of the Crude Extract of Xylocarpus granatum Stem Barks. Niger. J. Nat. Prod. Med. 2008, 11, 53–57. https://doi.org/10.4314/njnpm.v11i1.11882.

  • 38.

    Sarker, S.D.; Uddin, S.J.; Shilpi, J.A.; et al. Neuropharmacological properties of Xylocarpus moluccensis. Fitoterapia 2007, 78, 107–111. https://doi.org/10.1016/j.fitote.2006.09.029.

  • 39.

    Bernardo, J.; Ferreres, F.; Gil-Izquierdo, Á.; et al. In Vitro multimodal-effect of Trichilia catigua A. Juss. (Meliaceae) bark aqueous extract in CNS targets. J. Ethnopharmacol. 2018, 211, 247–255. https://doi.org/10.1016/j.jep.2017.09.039.

  • 40.

    Çiçek, S.S. Structure-Dependent Activity of Natural GABA(A) Receptor Modulators. Molecules 2018, 23, 1512. https://doi.org/10.3390/molecules23071512.

  • 41.

    Disha, I.J.; Hasan, R.; Bhuia, S.; et al. Anxiolytic Efficacy of Indirubin: In Vivo Approach along with Receptor Binding Profiling and Molecular Interaction with GABAergic Pathways. ChemistryOpen 2025, 14, e202400290. https://doi.org/10.1002/open.202400290.

  • 42.

    Bishwas, D.; Hasan, R.; Bhuia, M.S.; et al. Modulatory Anxiolytic Effect of Aucubin on Diazepam in Swiss Albino Mice: Possible Mechanisms through In Vivo Approach with Receptor Binding Affinity. Rev. Bras. Farmacogn. 2025, 35, 463–473. https://doi.org/10.1007/s43450-025-00629-9.

  • 43.

    Islam, M.T.; Al Hasan, M.S.; Chowdhury, R.; et al. Unveiling the anxiolytic and analgesic effects of citronellal in Swiss mice: In Vivo and in silico insights into COX and GABAA receptor pathways. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2025, 398, 5757–5771. https://doi.org/10.1007/s00210-024-03665-9.

  • 44.

    Thompson, S.M. Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: Past, present, and future. Neuropsychopharmacology 2024, 49, 83–95. https://doi.org/10.1038/s41386-023-01728-8.

  • 45.

    Brohan, J.; Goudra, B.G. The Role of GABA Receptor Agonists in Anesthesia and Sedation. CNS Drugs 2017, 31, 845–856. https://doi.org/10.1007/s40263-017-0463-7.

  • 46.

    Engin, E. GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Front. Psychiatry 2023, 13, 1060949. https://doi.org/10.3389/fpsyt.2022.1060949.

  • 47.

    Vinkers, C.H.; Klanker, M.; Groenink, L.; et al. Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress. Psychopharmacology 2009, 204, 299–311. https://doi.org/10.1007/s00213-009-1460-4.

  • 48.

    Islam, M.S.; Hossain, R.; Ahmed, T.; et al. Anxiolytic-like Effect of Quercetin Possibly through GABA Receptor Interaction Pathway: In Vivo and In Silico Studies. Molecules 2022, 27, 7149. https://doi.org/10.3390/molecules27217149.

  • 49.

    Islam, M.T.; de Freitas, R.M.; da Silva Oliveira, G.L.; et al. Neuropharmacological screenings of hydroalcoholic fractions of Urena lobata L. World J. Pharm. Pharm. Sci. 2014, 3, 62–71.

  • 50.

    Möhler, H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 2012, 62, 42–53. https://doi.org/10.1016/j.neuropharm.2011.08.040.

  • 51.

    Liberzon, I.; Phan, K.; Khan, S.; et al. Role of the GABAA Receptor in Anxiety: Evidence from animal models, molecular and clinical psychopharmacology, and brain imaging studies. Curr. Neuropharmacol. 2003, 1, 267–283. https://doi.org/10.2174/1570159033477071.

  • 52.

    Islam, M.T.; Al Hasan, M.S.; Ferdous, J.; et al. GabaAergic sedative prospection of sclareol-linalool co-treatment: An antagonistic intervention through in vivo and in silico studies. Neurosci. Lett. 2025, 845, 138060. https://doi.org/10.1016/j.neulet.2024.138060.

  • 53.

    Raihan, M.O.; Habib, M.R.; Brishti, A.; et al. Sedative and anxiolytic effects of the methanolic extract of Leea indica (Burm. f.) Merr. leaf. Drug Discov. Ther. 2011, 5, 185–189. https://doi.org/10.5582/ddt.2011.v5.4.185.

  • 54.

    Al Hasan, M.S.; Bhuia, M.S.; Chowdhury, R.; et al. Tangeretin enhances sedative activity of diazepam in Swiss mice through GABAA receptor interaction: In Vivo and in silico approaches. Neuroscience 2025, 572, 1–10. https://doi.org/10.1016/j.neuroscience.2025.03.004.

  • 55.

    Rakib, I.H.; Khan, M.S.; Ayub, A.; et al. Salvianolic acid A enhances sedative effect of diazepam through the GABAergic pathway: In Vivo, molecular docking, and pharmacokinetics approaches. Neurosci. Lett. 2025, 110, 107517. https://doi.org/10.1016/j.ntt.2025.107517.

Share this article:
How to Cite
Snigdha, H. M. S. H.; Chowdhury, R. I.; Saha, A. K.; Das, B.; Ahnaf, T. R.; Hoque, M. A.; Ahammed, S.; Hosain, Md. S.; Hossen, M. S.; Rouf, R.; Shilpi, J. A.; Islam, M. T.; Uddin, S. J. Neuropharmacological Evaluation of the Mangrove Plant Xylocarpus granatum J. Koenig Fruit Extract: Anxiolytic-Like and Sedative Profile in Murine Models. Natural Products Analysis 2026, 2 (2), 100020. https://doi.org/10.53941/npa.2026.100020.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.
Article Metrics
36
Article Views
0
Citations